Trials / Withdrawn
WithdrawnNCT05702788
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study to Evaluate the Efficacy and Safety of Jaktinib Hydrochloride Tablets in Participants Receiving the Best Available Treatment for Severe Novel Coronavirus Pneumonia
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib hydrochloride tablets | 75mg of Jaktinib administered orally Twice daily(BID) with best available treatment. |
| DRUG | Jaktinib hydrochloride tablets | 100mg of Jaktinib administered orally Twice daily(BID) with best available treatment. |
| OTHER | Placebo | Placebo (given as two placebo tablets) administered orally BID with best available treatment. |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2024-04-23
- Completion
- 2024-04-23
- First posted
- 2023-01-27
- Last updated
- 2024-04-26
Source: ClinicalTrials.gov record NCT05702788. Inclusion in this directory is not an endorsement.